Reports preliminary FY25 revenue $4.66B, consensus $4.64B. “We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance and the initial launch of our latest sensor technology with the G7 15 Day system,” said Jake Leach, Dexcom’s (DXCM) president and CEO. “With clinical momentum building across the CGM category, we look forward to extending our growth runway through continued innovation and evidence generation in 2026.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $86 from $84 at Bernstein
- Dexcom: Reset Expectations, Strengthened Fundamentals, and Operating Leverage Support Reiterated Buy Rating
- DexCom call volume above normal and directionally bullish
- Dexcom Names Jacob Leach as Incoming Chief Executive
- Claims Jabil losing share at Dexcom ‘not happening,’ says Raymond James